Past as Prologue-Use of Rubella Vaccination Program Lessons to Inform COVID-19 Vaccination
- PMID: 36502405
- PMCID: PMC9745252
- DOI: 10.3201/eid2813.220604
Past as Prologue-Use of Rubella Vaccination Program Lessons to Inform COVID-19 Vaccination
Abstract
The rapid rollout of vaccines against COVID-19 as a key mitigation strategy to end the global pandemic might be informed by lessons learned from rubella vaccine implementation in response to the global rubella epidemic of 1963-1965. That rubella epidemic led to the development of a rubella vaccine that has been introduced in all but 21 countries worldwide and has led to elimination of rubella in 93 countries. Although widespread introduction and use of rubella vaccines was slower than that for COVID-19 vaccines, the process can provide valuable insights for the continued battle against COVID-19. Experiences from the rubella disease control program highlight the critical and evolving elements of a vaccination program, including clearly delineated goals and strategies, regular data-driven revisions to the program based on disease and vaccine safety surveillance, and evaluations to identify the vaccine most capable of achieving disease control targets.
Keywords: COVID-19; Rubella vaccination; SARS-CoV-2; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine-preventable diseases; viruses; zoonoses.
Similar articles
-
Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa.Emerg Infect Dis. 2021 Aug;27(8):2009-2016. doi: 10.3201/eid2708.203870. Epub 2021 Jun 17. Emerg Infect Dis. 2021. PMID: 34138694 Free PMC article. Review.
-
Evaluation of Effectiveness of Global COVID-19 Vaccination Campaign.Emerg Infect Dis. 2022 Sep;28(9):1873-1876. doi: 10.3201/eid2809.212226. Epub 2022 Aug 1. Emerg Infect Dis. 2022. PMID: 35914516 Free PMC article.
-
Measles, mumps, rubella prevention: how can we do better?Expert Rev Vaccines. 2021 Jul;20(7):811-826. doi: 10.1080/14760584.2021.1927722. Epub 2021 Jun 7. Expert Rev Vaccines. 2021. PMID: 34096442 Review.
-
Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries.Papillomavirus Res. 2019 Dec;8:100172. doi: 10.1016/j.pvr.2019.100172. Epub 2019 Jun 8. Papillomavirus Res. 2019. PMID: 31185296 Free PMC article.
-
Epidemiological profile and progress toward rubella elimination in China. 10 years after nationwide introduction of rubella vaccine.Vaccine. 2018 Apr 12;36(16):2079-2085. doi: 10.1016/j.vaccine.2018.03.013. Epub 2018 Mar 14. Vaccine. 2018. PMID: 29550193
Cited by
-
Global Responses to the COVID-19 Pandemic.Emerg Infect Dis. 2022 Dec;28(13):S4-S7. doi: 10.3201/eid2813.221733. Emerg Infect Dis. 2022. PMID: 36502408 Free PMC article. Review. No abstract available.
References
-
- German measles at epidemic rate; city and state affected—2,302 cases reported here since Dec. 1; virus is termed mild; but women are warned of danger during first 3 months of pregnancy. New York Times. 1964;Feb 8:25.
-
- World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2020;95:306–324.
-
- World Health Organization. Measles and rubella global update November 2021. [cited 2021 Nov 18]. https://immunizationdata.who.int/assets/measles-rubella/Global_MR_Update...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous